JW (Cayman) Therapeutics Co. Ltd (JWCTF) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of JW (Cayman) Therapeutics Co. Ltd $0.05, price $0.20, upside -75.3%, quality 46 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch JW (Cayman) Therapeutics Co. Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $0.0004 – $2.85 · fair‑value band $0.0300 – $0.0600 · the $0.2022 price screens above the $0.0500 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow JW (Cayman) Therapeutics Co. in your weekly email
Every Wednesday you see whether JW (Cayman) Therapeutics Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People's Republic of China. The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer.
Show more
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People's Republic of China. The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer. It offers Carteyva, JWCAR201, and JWCAR239 for the treatment of hematological malignancies, advanced relmacabtagene autoleucel injection ("relma-cel") as a potential treatment for systemic lupus erythematosus ("SLE"), and progressed development of products for the treatment of solid tumors, as well as systemic lupus erythematosus (SLE), a chronic autoimmune disease. The company's products pipeline includes JWCAR129, a chimeric antigen receptor (CAR) construct therapy for use in the treatment of multiple myeloma; and JWCAR201, a dual targeting autologous CAR T-cell therapy for use in the treatment of B-cell malignancies and autoimmune diseases. It is also developing JWATM204 and JWATM214 for treating hepatocellular carcinoma (HCC); JWATM203 for the treatment of hepatoblastoma (HB) and hepatocellular carcinoma (HCC) in pediatric patients; JWATM213 for treating HCC; JWTCR001 for the treatment of various solid tumors; and JWCAR031 for the treatment of small cell lung cancer. In addition, the company engages in drug research and development; medical research and experimental development; import and export handling; and clinical trial and CRO, as well as investment holding activities. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China.
Stock analysis
JW (Cayman) Therapeutics Co. Ltd (JWCTF) currently trades at $0.2022, while our model-based Fair Value estimate is $0.0500, 75.3% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: $0.0300 (bear) to $0.0600 (bull), the price of $0.2022 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
JW (Cayman) Therapeutics Co. Ltd reported revenue of 276M CNY in FY2025 versus 30.8M CNY in FY2021, a compound +73.1%/yr. Reported net income was −541M CNY in FY2025.
Key figures
Market cap $98.9M · P/S ratio 0.35 · EPS (TTM) $−0.2000 · Net margin −196% · Return on equity −64.4% · Return on assets (EBIT) −28.7% · Operating margin −73.2% · Revenue (TTM) 284M CNY.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades about 62% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −75%, JWCTF screens richer than that median.
Fair Value models
Bear $0.0300Fair Value $0.0500Bull $0.0600
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.35/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+74.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.8%
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+178.1%
’18
’19
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−3,711.8% (2019) → −87.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare JW (Cayman) Therapeutics Co. Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks
Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score45 · Above median
Fair Value upside−85.5% · Bottom 25%
Profitability
Return on assets−11.4% · Below median
Net margin (TTM)−195.8% · Bottom 25%
Operating margin (TTM)−73.2% · Bottom 25%
Growth and dividend
Revenue growth148.3% · Top 25%
Balance sheet
Debt / equity0.03× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B0.18× · Cheapest 25%
P/S (TTM)0.35× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)98· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is JW (Cayman) Therapeutics Co. Ltd (JWCTF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.0500 versus the last price from Sep 25, 2026 of $0.2022, about −75% upside (overvalued).
What is the fair value of JWCTF?
Our model-based fair value for JW (Cayman) Therapeutics Co. Ltd is $0.0500 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $0.2022.
What is the quality score of JWCTF?
JW (Cayman) Therapeutics Co. Ltd has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for JW (Cayman) Therapeutics Co. Ltd (JWCTF)?
Our model-based price target is the fair value of $0.0500 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $0.0300, optimistic scenario $0.0600. It is a calculation from audited fundamentals, not an analyst target.
What is the JW (Cayman) Therapeutics Co. Ltd stock forecast for 2026?
Our models put fair value at $0.0500, about −75% upside versus the last price from Sep 25, 2026 of $0.2022 (overvalued). Cautious scenario $0.0300, optimistic scenario $0.0600. The calculation is refreshed regularly with new filings.
What is the revenue of JW (Cayman) Therapeutics Co. Ltd (JWCTF)?
JW (Cayman) Therapeutics Co. Ltd reported trailing-twelve-month revenue of about 284M CNY (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of JW (Cayman) Therapeutics Co. Ltd (JWCTF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For JW (Cayman) Therapeutics Co. Ltd it is $0.0500 per share (as of Sep 24, 2026), against a price of $0.2022. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is JW (Cayman) Therapeutics Co. Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, JWCTF trades above its calculated fair value: price $0.2022, fair value $0.0500, a gap of about −75% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of JWCTF?
No. The price is what the market pays today ($0.2022); the fair value is what the company's own numbers justify ($0.0500). For JW (Cayman) Therapeutics Co. Ltd the two are $0.1522 per share apart. That gap is exactly why we show both numbers side by side.
How much is JW (Cayman) Therapeutics Co. Ltd worth?
The market values JW (Cayman) Therapeutics Co. Ltd at about $98.9M (market capitalisation, as of Sep 24, 2026). Per share that is $0.2022; our models calculate a fair value of $0.0500 per share.
What do the bullish and bearish scenarios say about JWCTF?
Our models span a range for JW (Cayman) Therapeutics Co. Ltd: cautious scenario $0.0300, base $0.0500, optimistic $0.0600 per share (as of Sep 24, 2026, price $0.2022). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of JW (Cayman) Therapeutics Co. Ltd (JWCTF)?
Balance-sheet figures for JW (Cayman) Therapeutics Co. Ltd (as of Sep 24, 2026): return on equity −64.4%, debt of 0.03 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is JWCTF from its 52-week high?
JW (Cayman) Therapeutics Co. Ltd trades at $0.2022, about 62% below its 52-week high of $0.5346 and at the low of $0.2022 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0500 is for.
Which stocks are comparable to JW (Cayman) Therapeutics Co. Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is JW (Cayman) Therapeutics Co. Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price $0.2022, calculated fair value $0.0500 (−75%), Quality Score 46/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of JWCTF calculated?
We run JW (Cayman) Therapeutics Co. Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0500, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. JW (Cayman) Therapeutics Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of JW (Cayman) Therapeutics Co. Ltd (JWCTF)?
The latest price we hold is from Sep 25, 2026 and stands at $0.2022. Our model-based fair value is $0.0500, about −75% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with JW (Cayman) Therapeutics Co. Ltd right now?
The price sits above even our optimistic bull case ($0.0600). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (46/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($0.0300 to $0.0600) leaves room in how you read the outcome.
Key figures of JW (Cayman) Therapeutics Co. Ltd
How large is the market capitalisation of JW (Cayman) Therapeutics Co. Ltd (JWCTF)?
The market capitalisation of JW (Cayman) Therapeutics Co. Ltd is $98.9M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of JW (Cayman) Therapeutics Co. Ltd (JWCTF)?
The price-to-sales ratio of JW (Cayman) Therapeutics Co. Ltd is 0.35 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of JW (Cayman) Therapeutics Co. Ltd (JWCTF)?
Earnings per share at JW (Cayman) Therapeutics Co. Ltd are $−0.2000. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of JW (Cayman) Therapeutics Co. Ltd (JWCTF)?
The net margin of JW (Cayman) Therapeutics Co. Ltd is −196% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of JW (Cayman) Therapeutics Co. Ltd (JWCTF)?
The return on equity (ROE) of JW (Cayman) Therapeutics Co. Ltd is −64.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of JW (Cayman) Therapeutics Co. Ltd (JWCTF)?
On an EBIT basis the return on assets of JW (Cayman) Therapeutics Co. Ltd is −28.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of JW (Cayman) Therapeutics Co. Ltd (JWCTF)?
The operating margin of JW (Cayman) Therapeutics Co. Ltd is −73.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at JW (Cayman) Therapeutics Co. Ltd (JWCTF)?
Revenue at JW (Cayman) Therapeutics Co. Ltd is growing +148% versus a year earlier (3y avg +23.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does JW (Cayman) Therapeutics Co. Ltd (JWCTF) generate?
The free cash flow of JW (Cayman) Therapeutics Co. Ltd is −78.5M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does JW (Cayman) Therapeutics Co. Ltd (JWCTF) hold?
JW (Cayman) Therapeutics Co. Ltd holds more cash than debt, 241M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch JW (Cayman) Therapeutics Co. Ltd in the live analysis
One click puts JW (Cayman) Therapeutics Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 24, 2026